pituitary axis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-09 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Pedro Cuatrecasas (27 September 1936 – 19 March 2025) was a Spanish-born American biochemist and academic who was an adjunct professor of Pharmacology & Medicine at the University of California San Diego.
=== Mid-production reboot === On June 25, Bruce Malmuth left the movie, having only directed thirteen days. Production went dark for three days, after which he was replaced by Craig R. Baxley, who had recently directed I Come in Peace for Diamant. Baxley and Stonebridge were quickly sued for $2 million by Barry & Enright Productions, makers of the TV movie Not of This World, which Baxley had abandoned to take over The Brotherhood, but the dispute was resolved a few weeks later. Malmuth called the split a "non hostile, amicable" one, resulting from his push towards a psychological approach, which Baxley described as "almost too dark". An unnamed crew member told the Los Angeles Times of the influence wielded by Bosworth, and particularly Wichard, on set. Wichard himself took responsibility for streamlining the film, telling the paper: "some 17-year-old kid [was] going to say, 'Oh man, Boz, what are you doing?' I had to sell this movie. I had to give them what they expected." In a 2014 interview, however, Bosworth spoke highly of The Brotherhood's original vision, which had a large subplot dedicated to Huff's family, and deemed that the film would have been better for it. He instead blamed Malmuth and Leonetti's technical mistakes, which supposedly made their footage unusable. Others recalled the axed content in a much less favorable light. In his 2011 memoirs, Henriksen described his original dialogue, which largely consisted of Bible quotes, as "ridiculous", and pleaded with Baxley to let him change it as soon as he arrived.
== External links == [1] Apoptosis, Trail & Caspase 8 - The Proteolysis Map-animation PDB: 1D2Q TRAIL+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P50591 (Tumor necrosis factor ligand superfamily member 10) at the PDBe-KB.
Sources: en.wikipedia.org
=== Depolymerization techniques === Either chemical or enzymatic depolymerization techniques or a combination of the two underlie the vast majority of analyses carried out on the structure and function of heparin and heparan sulfate (HS).
is the density of reagent ions in absence of reactant molecules in the buffer gas, k is the reaction rate constant and t is the average time the ions need to pass the reaction region. With a PTR-MS instrument the number of product and of reagent ions can be measured, the reaction rate constant can be found in literature for most substances and the reaction time can be derived from the set instrument parameters. Therefore, the absolute concentration of trace constituents
In one study in aged men with prostate cancer, testosterone levels were initially suppressed by 70%, but increased to 50% of baseline levels between 6 and 12 months, remaining stable thereafter up to 24 months of therapy. The combination of progestogens like CPA with an estrogen is synergistic in terms of antigonadotropic effect, and is able to fully suppress gonadal testosterone production even with very small doses of the estrogen. One study found that 100 to 300 mg/day CPA combined with an "extremely low" dosage of diethylstilbestrol (0.1 mg/day), a nonsteroidal estrogen, suppressed testosterone levels into the castrate range (to 30 ng/dL) in men with prostate cancer. Discontinuation of diethylstilbestrol at 5 months resulted in a rapid 6-fold increase in testosterone levels (to 135 ng/dL) and then further (to almost 200 ng/dL) by 12 months. Another study likewise found that the combination of 160 mg/day oral megestrol acetate, a progestin closely related to CPA, with 0.5 to 1.5 mg/day oral estradiol suppressed testosterone levels into the castrate range in men with prostate cancer. A study by Fung and colleagues (2017) found no difference in suppression of circulating testosterone levels (~95% suppression) in transgender women by the combination of either 25 mg/day oral CPA or 50 mg/day oral CPA with a moderate dosage of oral or transdermal estradiol (mean 3.3 mg/day oral, 3.4 g/day gel, or 95.6 μg/day patches).
Sources: en.wikipedia.org
=== Irreversible inhibitors === Enzyme inhibitors can also irreversibly inactivate enzymes, usually by covalently modifying active site residues. These reactions, which may be called suicide substrates, follow exponential decay functions and are usually saturable. Below saturation, they follow first order kinetics with respect to inhibitor. Irreversible inhibition could be classified into two distinct types. Affinity labelling is a type of irreversible inhibition where a functional group that is highly reactive modifies a catalytically critical residue on the protein of interest to bring about inhibition. Mechanism-based inhibition, on the other hand, involves binding of the inhibitor followed by enzyme mediated alterations that transform the latter into a reactive group that irreversibly modifies the enzyme.
== Family == Cremer was born on 20 May 1900 in Munich, Germany into a family of scientists and university professors. She was the only daughter and middle child of Max Cremer and Elsbeth Rosmund. Her father, Max Cremer, was a professor of physiology and the inventor of the glass electrode. She had two brothers, Hubert Cremer, a mathematician, and Lothar Cremer, an acoustician.
Bryer defines the Druzes as ghulat of Isma'ilism, as they exaggerated the cult of the al-Hakim bi-Amr Allah and considered him divine. He also defines the Druze as a religion that deviated from Islam, noting that as a result of this deviation, the Druze faith "seems as different from Islam as Islam is from Christianity or Christianity is from Judaism". Despite originating from Isma'ilism, a branch of Islam, the Druze do not consider themselves Muslims, and they do not adhere to the Five Pillars of Islam. In terms of religious comparison, mainstream Christian denominations do not believe in reincarnation or the transmigration of the soul, contrary to the beliefs of the Druze; on the other hand, reincarnation is a paramount tenet in the Druze faith. Christianity teaches evangelism, often through the establishment of missions, unlike the Druze who do not accept converts to their faith. Marriage outside the Druze faith is rare and is strongly discouraged. Similarities between the Druze and Christians include commonalities in their view of monogamous marriage, as well as the forbidding of divorce and remarriage, in addition to the belief in the oneness of God and theophany. The Druze faith incorporates some elements of Christianity, and other religious beliefs.
=== International Cooperation === In February 2011, President Barack Obama and Canadian prime minister Stephen Harper issued a "Declaration on a Shared Vision for Perimeter Security and Economic Competitiveness" and announced the creation of the Canada-United States Regulatory Cooperation Council (RCC) "to increase regulatory transparency and coordination between the two countries." Under the RCC mandate, the FDA and Health Canada undertook a "first of its kind" initiative by selecting "as its first area of alignment common cold indications for certain over-the-counter antihistamine ingredients (GC 2013-01-10)." A more recent example of the FDA's international work is their 2018 cooperation with regulatory and law-enforcement agencies worldwide through Interpol as part of Operation Pangea XI. The FDA targeted 465 websites that illegally sold potentially dangerous, unapproved versions of opioid, oncology, and antiviral prescription drugs to U.S. consumers. The agency focused on transaction laundering schemes in order to uncover the complex online drug network.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.